HGS shares dip on FDA delay

Shares of Human Genome Sciences took a small hit Friday evening after the biotech company said that the FDA was extending its review time for the closely-watched lupus drug benlysta. While the drug was endorsed recently by an FDA panel, it's no great surprise that the agency needed more time to review the therapy as well as the panel vote. The target date for an agency decision is now March 10. Story

Suggested Articles

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.

AbbVie and Roche alum Janet Hammond, M.D., Ph.D., Sc.M., F.C.P. has nabbed the chief development officer role at infectious disease biotech Atea.